drugset
drugset / Trial / NCT03922555

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

NCT03922555 ↗

Phase 1 Recruiting 18 enrolled Massachusetts General Hospital Astex Pharmaceuticals, Inc. · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

this research study is evaluating the highest dose of ASTX727 that can be administered safely to recurrent/progressive non-enhancing IDH mutant gliomas patients.

Timeline

Start
2019-07-12
Primary completion
2027-01-01
Completion
2028-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Decitabine Small molecule — Oral
Background Cedazuridine Small molecule — Oral

Indications

nervous system cancer